CA 15-3: a prognostic marker in breast cancer

被引:93
作者
Duffy, MJ [1 ]
Shering, S
Sherry, F
McDermott, E
O'Higgins, N
机构
[1] St Vincents Univ Hosp, Dept Nucl Med, Dublin 4, Ireland
[2] Univ Coll Dublin, Dept Surg, Dublin 2, Ireland
关键词
breast cancer; tumor markers; CA; 15-3; MUC1; prognosis;
D O I
10.1177/172460080001500410
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
CA 15-3 (also known as MUC1) is the most widely used serum marker in breast cancer. MUC1 is a large transmembrane glycoprotein which is frequently overexpressed and aberrantly glycosylated in cancer. Physiologically, MUC1 appears to play a role in cell adhesion and the high levels present in cancer may be causally involved in metastasis. At present the main uses of CA 15-3 are in preclinically detecting recurrent breast cancer and monitoring the treatment of patients with advanced breast cancer. In a prospective study of 368 patients we show that patients with high preoperative levels of CA 15-3 (>30.4 U/mL) had a worse outcome than patients with low levels of the marker. In multivariate analysis CA 15-3 as a prognostic marker was independent of both tumor size and nodal status. Furthermore, in multivariate analysis the prognostic impact of CA 15-3 was stronger than that of tumor size and at least as strong as nodal status. CA 15-3 may thus be the first independent prognostic serum marker in breast cancer.
引用
收藏
页码:330 / 333
页数:4
相关论文
共 24 条
  • [1] PROGNOSTIC VALUE IN PREDICTING OVERALL SURVIVAL OF 2 MUCINOUS MARKERS - CA-15-3 AND CA-125 IN BREAST-CANCER PATIENTS AT FIRST RELAPSE OF DISEASE
    BERRUTI, A
    TAMPELLINI, M
    TORTA, M
    BUNIVA, T
    GORZEGNO, G
    DOGLIOTTI, L
    [J]. EUROPEAN JOURNAL OF CANCER, 1994, 30A (14) : 2082 - 2084
  • [2] CA 15-3 and related mucins as circulating markers in breast cancer
    Duffy, MJ
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 1999, 36 : 579 - 586
  • [3] Duffy MJ, 1996, CLIN CANCER RES, V2, P613
  • [4] DUFFY MJ, 1990, CLIN CHEM, V36, P189
  • [5] DUFFY MJ, 2000, IN PRESS J CLIN LIG
  • [6] DUFFY MJ, 1996, P 16 INT C CLIN CH A, V407, P147
  • [7] Ebeling FC, 1999, ANTICANCER RES, V19, P2545
  • [8] Prognostic and predictive value of p53 and p21 in breast cancer
    Elledge, RM
    Allred, DC
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) : 79 - 98
  • [9] CELL MEMBRANE-ASSOCIATED MUCINS AND THEIR ADHESION-MODULATING PROPERTY
    HILKENS, J
    LIGTENBERG, MJL
    VOS, HL
    LITVINOV, SV
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 1992, 17 (09) : 359 - 363
  • [10] HOROBIN J M, 1991, Journal of the Royal College of Surgeons of Edinburgh, V36, P219